The Systemic Gap in Reproductive Healthcare
Female genital schistosomiasis (FGS) represents a critical failure in the current delivery of reproductive health services across endemic regions. Caused by the parasitic worm Schistosoma haematobium, the disease manifests when parasite eggs lodge in reproductive tissues, triggering chronic inflammation and scarring. Despite affecting an estimated 40 million women and girls, primarily in sub-Saharan Africa, the condition remains largely invisible within standard clinical protocols and national reproductive health strategies.
The persistence of FGS is closely tied to systemic deficits in water, sanitation, and hygiene (WASH) infrastructure. Because the parasite is transmitted through contact with infested freshwater, the risk is inextricably linked to socioeconomic factors and the necessity of using contaminated water sources for domestic and occupational activities. In practice, this means that ministries of health cannot tackle FGS without coordinated investment from water and infrastructure authorities-a governance gap that has kept the disease at the margins of policy priorities.
Professor Amaya Bustinduy, Professor of Global Pediatric and Adolescent Infectious Diseases at LSHTM and senior author on the paper, stated: “Female genital schistosomiasis remains one of the most neglected gynecological conditions affecting women and girls in Africa. Despite the scale of the problem, it is still routinely overlooked within both neglected tropical disease programs and wider sexual and reproductive healthcare services.”
Compounding Risks and Viral Vulnerability
The clinical impact of FGS extends beyond localized tissue damage to reshape the risk landscape for other infections. Emerging evidence suggests a synergistic relationship between parasitic inflammation and the susceptibility to viral infections, including HIV and human papillomavirus (HPV). The chronic lesions and scarring caused by S. haematobium can compromise the mucosal barrier of the reproductive tract, potentially facilitating the entry and persistence of other pathogens and undermining the effectiveness of national HIV and cervical cancer prevention plans.
| Factor | Public Health Impact |
|---|---|
| Mucosal Inflammation | Increases vulnerability to HIV acquisition and transmission, with implications for national HIV incidence targets. |
| Tissue Scarring | May alter the local environment, potentially complicating the detection and interpretation of cervical abnormalities in screening programmes. |
| HPV Co-infection | Heightened risk of human papillomavirus (HPV) persistence, a primary driver of cervical cancer, threatening progress on WHO’s elimination targets. |
| Diagnostic Neglect | Untreated FGS undermines the efficacy of broader sexual and reproductive health (SRH) goals and distorts surveillance data used for policy decisions. |
Integrating Diagnostics into Primary Care
To address the scale of the epidemic, public health frameworks must move away from “vertical” or disease-specific programs. Current models often treat neglected tropical diseases (NTDs) in isolation from general reproductive health services, creating a fragmented care pathway that fails to identify co-infections and wastes scarce diagnostic capacity. This fragmentation persists despite the existence of the World Health Organization’s road map for neglected tropical diseases 2021-2030, which explicitly calls for integrated, cross-programme approaches.
Improving outcomes requires a transition toward integrated diagnostic hubs at primary care level. By utilizing a single genital sample to screen for both HPV and FGS, healthcare systems can maximize limited resources, reduce the number of clinical visits required, and increase the likelihood of early detection. For health ministries and donors, this offers a rare efficiency gain: one visit, one sample, multiple answers.
This transition depends on several critical infrastructure and governance upgrades:
- Workforce Capacity: Expanding training for frontline healthcare workers, including nurses, midwives and clinical officers, to recognize the clinical signs of FGS and to refer cases through clear national protocols.
- Technological Adoption: Implementing molecular diagnostics and AI-supported tools to reduce reliance on invasive or outdated microscopy, and to enable task-shifting in low-resource clinics.
- Policy Alignment: Aligning NTD funding with sexual and reproductive health (SRH) budgets to ensure sustainable screening, and embedding FGS indicators within national health information systems.
Professor Russell Stothard, Professor of Medical Parasitology at LSTM and co-author of the paper, said: “This paper highlights the urgent need to move beyond isolated disease-specific approaches and towards integrated care that recognizes the overlap between FGS, HIV, HPV and other reproductive health conditions.”
Zoonotic Evolution and One Health Imperatives
Recent findings from the Hybridisation in Urogenital Schistosomiasis (HUGS) study in Malawi have introduced a new layer of complexity: the emergence of zoonotic and hybrid schistosome species. Parasites typically associated with livestock have been detected in human genital samples, suggesting that the boundary between animal and human parasitic infections is blurring and that traditional human-only control strategies may be insufficient.
This evolutionary shift presents significant regulatory and clinical challenges, as existing treatment protocols and mass drug administration (MDA) guidelines are designed for human-specific strains. If hybrid species exhibit different drug sensitivities, current MDA strategies may see reduced effectiveness, forcing regulators and national control programmes to revisit drug policies, dosing schedules and surveillance requirements.
Professor Stothard added: “The emergence of zoonotic and hybrid schistosome species also reinforces the importance of One Health approaches that consider human, animal and environmental health together.”
Addressing FGS now requires a multisectoral strategy that integrates veterinary surveillance, environmental management of freshwater sources, and clinical reproductive care. For governments, that means aligning ministries of health, agriculture and environment behind shared surveillance data and joint planning cycles, rather than treating FGS as a narrow clinical issue. Without such coordination, the burden of FGS will remain hidden in plain sight-eroding progress on HIV, cervical cancer and broader women’s health commitments across endemic countries.
